Etherna Immunotherapies SA
52.1 FTEEtherna Immunotherapies reported revenue of €8.79m for the 2025 financial year (annual accounts filed with the NBB on 29 May 2026), with 52.1 full-time equivalents.
The score of Etherna Immunotherapies shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Revenue +114 % Total assets -49 % Headcount (avg FTE) -19 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Etherna Immunotherapies's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €8.79m | ||||
| Net result | −€4.27m | ||||
| Equity | −€3.91m | ||||
| Cash | €2.42m | ||||
| EBITDA | €2.64m | ||||
| Total assets | €12.8m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 May 2026
- Year ended 31 Dec 2024filed on 27 May 2025
- Year ended 31 Dec 2023filed on 07 May 2024
- Year ended 31 Dec 2022filed on 09 May 2023
- Year ended 31 Dec 2021filed on 23 May 2022
Etherna Immunotherapies's financial analysis
- Solvency-30.6%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Etherna Immunotherapies
11 active director(s) in the register.
and 5 more
Etherna Immunotherapies's shareholders and holdings →Etherna Immunotherapies's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0502.703.389
- VAT number
- BE0502703389
- Peppol
- Registered · 0208:0502703389 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 21 Jan 2013
- Registered office
- 2845 Niel
- Size
- Medium · 52.1 FTE
- Latest accounts
- 2025 · filed on 29 May 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
Etherna Immunotherapies (SA) has been based in Niel since 2013, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports revenue of €8.79m, a net loss of €4.27m and equity of −€3.91m. With 52.1 full-time equivalents, it is a medium-sized enterprise by headcount. Its solvency stands at -30.6%, below the median of its sector (60.4%).
Guide: Checking a Belgian supplier invoice: numbers and IBAN →
Companies similar to Etherna Immunotherapies
Companies in the same business, of comparable size and area, outside its group.
- EXO Biologics Research and experimental development on natural sciences and engineering Liège · balance sheet €11.7m
- Phoenix Biosciences Manufacture of pharmaceutical preparations Nivelles · balance sheet €8.11m
- ATB Therapeutics Manufacture of basic pharmaceutical products Marche-en-Famenne · balance sheet €10.6m
- White Raven Manufacture of pharmaceutical preparations Liège · balance sheet €9.55m
- Swedish Orphan Biovitrum (Belgium) Business and other management consultancy activities Zaventem · balance sheet €11.0m
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
- Unisensor Manufacture of basic pharmaceutical products Seraing · balance sheet €19.2m
- Univercells Technologies Manufacture of other chemical products n.e.c. Nivelles · balance sheet €16.2m
Frequently asked questions about Etherna Immunotherapies
What is the revenue of Etherna Immunotherapies?
According to the 2025 annual accounts filed with the NBB, the revenue of Etherna Immunotherapies amounts to 8,788,056 €.
What is the VAT number of Etherna Immunotherapies?
In Belgium, the VAT number is the company number prefixed with BE: BE0502703389 for Etherna Immunotherapies, if the company is VAT-registered. Its company number (CBE) is 0502.703.389.
Where is the registered office of Etherna Immunotherapies?
According to the CBE register, the registered office of Etherna Immunotherapies is in 2845 Niel.
What is the equity of Etherna Immunotherapies?
At the close of the 2025 financial year, the equity of Etherna Immunotherapies amounts to -3,907,881 €, a solvency of -30.6% of total assets.
How many people work at Etherna Immunotherapies?
52.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Etherna Immunotherapies?
The register lists 11 active mandates at Etherna Immunotherapies. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Etherna Immunotherapies
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →